A single-arm, single center phase II trial of bendamustine/rituximab induction followed by venetoclax and rituximab consolidation for the frontline treatment of chronic lymphocytic leukemia
Study of Bendamustine/Rituximab Induction Followed by Venetoclax and Rituximab Consolidation for Treatment of Chronic Lymphocytic Leukemia
Sponsor: AbbVie
Enrolling: Male and Female Patients
IRB Number: AAAR6357
U.S. Govt. ID: NCT03609593
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this study is to determine the effectiveness of the study treatment- bendamustine and rituximab (BR) followed by venetoclax for 12 months. The combination of the drugs bendamustine and rituximab is a commonly used treatment for your disease. Venetoclax is an oral drug that blocks a protein called BCL-2 which is present on CLL cells. With this combination, we hope to increase response to therapy and reduce the risk of tumor lysis syndrome. In addition, we hope to reduce the total time on therapy by limiting treatment with venetoclax to 12 months in duration. Cancers include chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
This study is closed
Nicole Lamanna, MD
Do You Qualify?
Are you 18 years of age or older? Yes No
Do you have a diagnosis of CLL or SLL? Yes No
Have you had prior treatment for your disease? Yes No
Do you have adequate organ function? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator